Treefrog Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
144
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
20
Treefrog Therapeutics General Information
Description
Developer of a proprietary technology platform designed to provide alternative access to cell therapies. The company's tool provides an end-to-end, three-dimensional scalable service that will reduce treatment costs as well as help cell therapy players secure cell production and quality, accelerate clinical development, and facilitate market access, enabling patients to access safe and affordable stem cell therapy.
Contact Information
Website
www.treefrog.frCorporate Office
- 30 Avenue Gustave Eiffel Bâtiment A
- 33600 Pessac
- France
Corporate Office
- 30 Avenue Gustave Eiffel Bâtiment A
- 33600 Pessac
- France
Treefrog Therapeutics Timeline
Treefrog Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Accelerator/Incubator | 01-Jan-2025 | Completed | Generating Revenue | |||
| 12. Debt - General | 27-Nov-2024 | Completed | Generating Revenue | |||
| 11. Later Stage VC | 03-Jan-2023 | Completed | Generating Revenue | |||
| 10. Early Stage VC (Series B) | 13-Sep-2021 | Completed | Generating Revenue | |||
| 9. Accelerator/Incubator | 01-Jan-2020 | Completed | Generating Revenue | |||
| 8. Grant | 09-Sep-2019 | Completed | Generating Revenue | |||
| 7. Early Stage VC (Series A) | 13-May-2019 | Completed | Generating Revenue | |||
| 6. Grant | 01-Mar-2019 | Completed | Generating Revenue | |||
| 5. Seed Round | 09-Jan-2019 | $673K | $673K | Completed | Generating Revenue | |
| 4. Accelerator/Incubator | 01-Jan-2019 | Completed | Generating Revenue |
Treefrog Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Series A | ||||||||
| Ordinary | 11,800 | $1.121089 | $56.05 | $56.05 | 1x | $56.05 | 10.55% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Treefrog Therapeutics Comparisons
Industry
Financing
Details
Treefrog Therapeutics Competitors (45)
One of Treefrog Therapeutics’s 45 competitors is iXCells Biotechnologies, a Private Equity-Backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| iXCells Biotechnologies | Private Equity-Backed | San Diego, CA | ||||
| Regenerative Medical Solutions | Venture Capital-Backed | Madison, WI | ||||
| Sernova Biotherapeutics | Corporation | Mississauga, Canada | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ | ||||
| GenSight Biologics | Formerly VC-backed | Paris, France |
Treefrog Therapeutics Patents
Treefrog Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260209690-A1 | Method for treating crosslinked microcompartments comprising biological elements | Pending | 22-Jan-2025 | ||
| WO-2026159210-A1 | Method for treating crosslinked microcompartments comprising biological elements | Pending | 22-Jan-2025 | ||
| FR-3171449-A1 | Process for treating cross-linked microcompartments comprising biological elements | Pending | 22-Jan-2025 | ||
| WO-2026139294-A1 | Cell encapsulation system comprising solution dispensers | Pending | 23-Dec-2024 | ||
| FR-3170504-A1 | Cell encapsulation system incorporating solution dispensers | Pending | 23-Dec-2024 | C12M25/16 |
Treefrog Therapeutics Signals
Treefrog Therapeutics Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| LabCentral | Accelerator/Incubator | |||
| AustralianSuper | Limited Partner | Minority | ||
| BNP Paribas Développement | PE/Buyout | Minority | ||
| Nouvelle Aquitaine Co-Investissement | Venture Capital | Minority | ||
| Resonance VC | Venture Capital | Minority |
Treefrog Therapeutics FAQs
-
When was Treefrog Therapeutics founded?
Treefrog Therapeutics was founded in 2018.
-
Where is Treefrog Therapeutics headquartered?
Treefrog Therapeutics is headquartered in Pessac, France.
-
What is the size of Treefrog Therapeutics?
Treefrog Therapeutics has 144 total employees.
-
What industry is Treefrog Therapeutics in?
Treefrog Therapeutics’s primary industry is Drug Discovery.
-
Is Treefrog Therapeutics a private or public company?
Treefrog Therapeutics is a Private company.
-
What is Treefrog Therapeutics’s current revenue?
The current revenue for Treefrog Therapeutics is .
-
How much funding has Treefrog Therapeutics raised over time?
Treefrog Therapeutics has raised $116M.
-
Who are Treefrog Therapeutics’s investors?
LabCentral, AustralianSuper, BNP Paribas Développement, Nouvelle Aquitaine Co-Investissement, and Resonance VC are 5 of 20 investors who have invested in Treefrog Therapeutics.
-
Who are Treefrog Therapeutics’s competitors?
iXCells Biotechnologies, Regenerative Medical Solutions, Sernova Biotherapeutics, Lisata Therapeutics, and GenSight Biologics are some of the 45 competitors of Treefrog Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process